معرفی
Vladimir Coric, MD, is an Associate Clinical Professor of Psychiatry at Yale School of Medicine and Chief Executive Officer of Biohaven Pharmaceutical Holding Company. He specializes in neurodegenerative diseases, clinical trials, and drug development, with a focus on Parkinson’s, Alzheimer’s, and ataxia. His research involves developing composite scales for disease progression assessment and evaluating therapies like troriluzole and taldefgrobep alfa.
Education: MD from Wake Forest University (1996), Yale Psychiatry Residency (2000), and Chief Resident at the National Center for PTSD (2000). Awards include the 2018 Ernst & Young Entrepreneur of the Year (New York region). He has authored over 90 publications, emphasizing neurology, clinical pharmacology, and translational medicine.
Key roles: Leader in Biohaven’s clinical-stage biopharmaceutical efforts targeting neurological disorders. His work bridges academia and industry, focusing on unmet medical needs in neurology. Collaborations include studies on biomarkers, disease progression metrics, and novel drug candidates.
